v3 Template
R

Roivant

Biotechnology and Healthcare BASEL, Switzerland and LONDON and NEW YORK ~440 employees
Founded
--
Employees (Est.)
~440
22 leaders known
Total Funding
$350.0M
Funding Rounds
2
Last Funding
2023-02-02

About Roivant

Roivant Sciences is focused on reinventing the discovery, development, and commercialization of new medicines. They develop transformative medicines and technologies by building agile, focused companies called Vants, aligning incentives to drive fast, high-quality execution and rigorous capital allocation.

Products & Services

Immunovant:Advancing potentially transformative therapies for autoimmune diseases.
Priovant:Developing targeted therapies for patients with severe autoimmune disease.
Pulmovant:Committed to transforming the lives of patients with pulmonary diseases.
Pipeline:Advancing a broad and differentiated pipeline of investigational drugs.

Specialties

Drug Discovery Drug Development Commercialization of Medicines Autoimmune Diseases Pulmonary Diseases Technology in Healthcare

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Public Offering
T: -
FT: Public Offering 		A: 200000000
MR: -
FA: $200 million
FAN: 200000000 		D: 2023-02-02
FD: 2023-02-02 		4 investors
2 RT: Public Offering
T: -
FT: Public Offering 		A: 150000000
MR: -
FA: $150 million
FAN: 150000000 		D: 2023-02-01
FD: 2023-02-01 		4 investors
Public Offering Latest
2023-02-02
$200.0M
4 investors (Pro only)
Public Offering 2023-02-01
$150.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

M

Matt Gline

Chief Executive Officer

LinkedIn (Pro only)
A

Alex Gasner

EVP, Roivant Health

LinkedIn (Pro only)
D

Daniel Gold

Director

LinkedIn (Pro only)
E

Eric Valeur

Vice President, Head of Drug Discovery

E

Eric Venker

Roivant President and Immunovant CEO

F

Frank Torti

Vant Chair

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

Roivant Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology and Healthcare
Company Size
~440 employees (est.)
Locations
BASEL, Switzerland and LONDON and NEW YORK
Basel, Switzerland; London; New York
New York

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro